Индивидуальный выбор менопаузальной гормональной терапии

Овсянникова Т.В., Куликов И.А. Индивидуальный выбор менопаузальной гормональной терапии. Гинекология. 2016; 18 (4): 59–62.

________________________________________________

Ovsyannikova T.V., Kulikov I.A. Individual choice of menopausal hormone therapy. Gynecology. 2016; 18 (4): 59–62.

Читать PDF

Аннотация

Цель антивозрастной менопаузальной гормональной терапии (МГТ) – поддержание и восстановление деятельности важнейших органов и систем организма, благодаря чему достигаются два основных эффекта: увеличивается продолжительность жизни и улучшается ее качество, что полностью соответствует желаниям женщин в пери- и постменопаузе. МГТ, начатая в периоде менопаузального перехода, – это не только терапия ранних симптомов климактерия, но и профилактика поздних осложнений постменопаузы. В статье рассмотрены возможности и эффективность применения препарата Анжелик® Микро, содержащего сниженные дозы эстрогенов и прогестагена (17b-эстрадиол 0,5 мг + дроспиренон 0,25 мг). Показаниями для его назначения является сохранение умеренных и тяжелых приливов в постменопаузе у женщин с интактной маткой.

Ключевые слова: менопаузальная гормональная терапия, постменопауза, Анжелик Микро.

________________________________________________

The goal of anti-aging menopausal hormone therapy (MHT) lies in maintenance and restoration of the major organs and body systems, thus achieving two main effects: increasing life expectancy and improving its quality, which is fully consistent with the desires of women in perimenopausal and postmenopausal women. MHT started in the menopausal transition period is not only the treatment of early symptoms of menopause, but menopause itself and prevention of late complications. The article discusses the possibility and efficacy of Angeliq® Micro containing reduced doses of estrogen and progestogen (17β-estradiol 0.5 mg + drospirenone 0.25 mg). Indications for its purpose is to maintain moderate to severe hot flashes in postmenopausal women with an intact uterus.

Key words: menopausal hormone therapy, postmenopause, Angeliq Micro.

Полный текст

Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.

Список литературы

1. http://vz.ru/news/2016/2/11/793605.html
2. Менопаузальная гормонотерапия и сохранение здоровья женщин зрелого возраста. Клинические рекомендации. М., 2014. / Menopauzal'naia gormonoterapiia i sokhranenie zdorov'ia zhenshchin zrelogo vozrasta. Klinicheskie rekomendatsii. M., 2014. [in Russian]
3. Попова С.М., Яник А.А. Проблемы глобального старения населения: анализ документов и стратегии ООН Международное право и международные организации. Int Law Int Organiz 2014; 3: 429–43. DOI: 10.7256/2226-6305.2014.3.12857 / Popova S.M., Ianik A.A. Problemy global'nogo stareniia naseleniia: analiz dokumentov i strategii OON Mezhdunarodnoe pravo i mezhdunarodnye organizatsii. Int Law Int Organiz 2014; 3: 429–43. DOI: 10.7256/2226-6305.2014.3.12857 [in Russian]
4. Lobo RA, Davis SR, De Villiers TJ et al. Prevention of diseases after menopause. Climacteric 2014;17 (5): 540–56. DOI: 10.3109/13697137.2014.933411. Epub 2014 Jun 27.
5. .http://www.fundshub.ru/
6. http://worktips.ru/pochemu-vygodno-brat-na-rabotu-50-letnix/
7. http://fevt.ru/load/rabochee_vremja/100-1-0-1495
8. http://ecouniver.com/7625-cel-organizacii-rabochego-mesta-zhenshhin.html
9. Avis NE, Crawford SL, Greendale G. Study of Women's Health Across the Nation. Duration of menopausal vasomotor symptoms over the menopause transition. JAMA Intern Med 2015; 175 (4): 531–9. DOI: 10.1001/jamainternmed.2014.8063.
10. Bardel A, Wallander MA, Wedel H, Svärdsudd K. Age-specific symptom prevalence in women 35–64 years old: a population-based study. BMC Public Health 2009; 9: 37. DOI: 10.1186/1471-2458-9-37
11. Pinkerton JV, Abraham L, Bushmakin AG et al. Relationship between changes in vasomotor symptoms and changes in menopause-specific quality of life and sleep parameters. Menopause 2016; Jul 11. [Epub ahead of print]
12. Freeman EW, Sammel MD, Sanders RJ. Risk of long-term hot flashes after natural menopause: evidence from the Penn Ovarian Aging Study cohort. Menopause 2014; 21 (9): 924–32. DOI: 10.1097/GME.0000000000000196
13. Hodis HN, Mack WJ, Henderson VWN. ELITE Research Group. Vascular Effects of Early versus Late Postmenopausal Treatment with Estradiol. Engl J Med; 374 (13): 1221–31. DOI: 10.1056/NEJMoa1505241
14. Abdi F, Mobedi H, Mosaffa N. Hormone Therapy for Relieving Postmenopausal Vasomotor Symptoms: A Systematic. Arch Iran Med 2016; 19 (2): 141–6. DOI: 0161902/AIM.0013
15. http://pikabu.ru/story/prichinyi_smerti_naseleniya_v_rf_v_2014_
godu_3428488
16. Yoon PW, Bastian B, Anderson RN et al. Centers for Disease Control and Prevention (CDC). Potentially preventable deaths from the five leading causes of death – United States, 2008–2010. MMWR Morb Mortal Wkly Rep 2014; 63 (17): 369–74.
17. Benkhadra K, Mohammed K, Al Nofal A. et al. Menopausal Hormone Therapy and Mortality: A Systematic Review and Meta-Analysis. J Clin Endocrinol Metab 2015; 100 (11): 4021–8. DOI: 10.1210/jc.2015-2238.
18. Mikkola TS, Tuomikoski P, Lyytinen H. Estradiol-based postmenopausal hormone therapy and risk of cardiovascular and all-cause mortality. Menopaus 2015; 22 (9): 976–83. DOI: 10.1097/GME.0000000000000450
19. Сметник В.П., Балан В.Е., Зайдиева Я.З. и др. Ведение женщин с сердечно-сосудистым риском в пери- и постменопаузе. Рос. кардиологический журн. 2008; 4: 40–57. / Smetnik V.P., Balan V.E., Zaidieva Ia.Z. i dr. Vedenie zhenshchin s serdechno-sosudistym riskom v peri- i postmenopauze. Ros. kardiologicheskii zhurn. 2008; 4: 40–57. [in Russian]
20. Collins P, Webb CM1, de Villiers TJ еt al. Cardiovascular risk assessment in women – an update. Climacteric 2016; 19 (4): 329–36. DOI: 10.1080/13697137.2016.1198574. Epub 2016 Jun 21
21. Gass ML, Maki PM, Shifren JL et al. NAMS supports judicious use of systemic hormone therapy for women aged 65 years and older. Menopause 2015; 22 (7): 685–6. DOI: 10.1097/GME.0000000000000491
22. Schürmann R, Holler T, Benda N. Estradiol and drospirenone for climacteric symptoms in postmenopausal women: a double-blind, randomized, placebo-controlled study of the safety and efficacy of three dose regimens. Climacteric 2004; 7 (2): 189–96.
23. Gambacciani M, Rosano G, Cappagli B. Clinical and metabolic effects of drospirenone-estradiol in menopausal women: a prospective study. Climacteric 2011; 14 (1): 18–24. DOI: 10.3109/13697137.2010.520099. Epub 2010 Oct 27.
24. AGOS Practice BULLETTIN No 141: Management Of Menopausal Symptoms. Obstet Gynecol 2014; 123–202–216.
25. Инструкция по применению препарата Анжелик Микро. http://www.rlsnet.ru/tn_index_id_80329.htm / Instruktsiia po primeneniiu preparata Anzhelik Mikro. http://www.rlsnet.ru/tn_index_id_80329.htm [in Russian]
26. Archer DF, Schmelter Th, Schaefers M et al. A randomized, double-blind, placebo-controlled study of the lowest effective dose of drospirenone with 17b-estradiol for moderate to severe vasomotor symptoms in postmenopausal women. Menopause 2014; 21 ( 3): 227–35.DOI: 10.1097/GME.0b013e31829c1431
27. Genazzani AR, Schmelter T, Schaefers M. One-year randomized study of the endometrial safety and bleeding pattern of 0.25 mg drospirenone/0.5 mg 17b-estradiol in postmenopausal women. Climacteric 2013; 16: 490–8. DOI: 10.1056/NEJMoa1505241

________________________________________________

1. http://vz.ru/news/2016/2/11/793605.html
2. Menopauzal'naia gormonoterapiia i sokhranenie zdorov'ia zhenshchin zrelogo vozrasta. Klinicheskie rekomendatsii. M., 2014. [in Russian]
3. Popova S.M., Ianik A.A. Problemy global'nogo stareniia naseleniia: analiz dokumentov i strategii OON Mezhdunarodnoe pravo i mezhdunarodnye organizatsii. Int Law Int Organiz 2014; 3: 429–43. DOI: 10.7256/2226-6305.2014.3.12857 [in Russian]
4. Lobo RA, Davis SR, De Villiers TJ et al. Prevention of diseases after menopause. Climacteric 2014;17 (5): 540–56. DOI: 10.3109/13697137.2014.933411. Epub 2014 Jun 27.
5. .http://www.fundshub.ru/
6. http://worktips.ru/pochemu-vygodno-brat-na-rabotu-50-letnix/
7. http://fevt.ru/load/rabochee_vremja/100-1-0-1495
8. http://ecouniver.com/7625-cel-organizacii-rabochego-mesta-zhenshhin.html
9. Avis NE, Crawford SL, Greendale G. Study of Women's Health Across the Nation. Duration of menopausal vasomotor symptoms over the menopause transition. JAMA Intern Med 2015; 175 (4): 531–9. DOI: 10.1001/jamainternmed.2014.8063.
10. Bardel A, Wallander MA, Wedel H, Svärdsudd K. Age-specific symptom prevalence in women 35–64 years old: a population-based study. BMC Public Health 2009; 9: 37. DOI: 10.1186/1471-2458-9-37
11. Pinkerton JV, Abraham L, Bushmakin AG et al. Relationship between changes in vasomotor symptoms and changes in menopause-specific quality of life and sleep parameters. Menopause 2016; Jul 11. [Epub ahead of print]
12. Freeman EW, Sammel MD, Sanders RJ. Risk of long-term hot flashes after natural menopause: evidence from the Penn Ovarian Aging Study cohort. Menopause 2014; 21 (9): 924–32. DOI: 10.1097/GME.0000000000000196
13. Hodis HN, Mack WJ, Henderson VWN. ELITE Research Group. Vascular Effects of Early versus Late Postmenopausal Treatment with Estradiol. Engl J Med; 374 (13): 1221–31. DOI: 10.1056/NEJMoa1505241
14. Abdi F, Mobedi H, Mosaffa N. Hormone Therapy for Relieving Postmenopausal Vasomotor Symptoms: A Systematic. Arch Iran Med 2016; 19 (2): 141–6. DOI: 0161902/AIM.0013
15. http://pikabu.ru/story/prichinyi_smerti_naseleniya_v_rf_v_2014_
godu_3428488
16. Yoon PW, Bastian B, Anderson RN et al. Centers for Disease Control and Prevention (CDC). Potentially preventable deaths from the five leading causes of death – United States, 2008–2010. MMWR Morb Mortal Wkly Rep 2014; 63 (17): 369–74.
17. Benkhadra K, Mohammed K, Al Nofal A. et al. Menopausal Hormone Therapy and Mortality: A Systematic Review and Meta-Analysis. J Clin Endocrinol Metab 2015; 100 (11): 4021–8. DOI: 10.1210/jc.2015-2238.
18. Mikkola TS, Tuomikoski P, Lyytinen H. Estradiol-based postmenopausal hormone therapy and risk of cardiovascular and all-cause mortality. Menopaus 2015; 22 (9): 976–83. DOI: 10.1097/GME.0000000000000450
19. Smetnik V.P., Balan V.E., Zaidieva Ia.Z. i dr. Vedenie zhenshchin s serdechno-sosudistym riskom v peri- i postmenopauze. Ros. kardiologicheskii zhurn. 2008; 4: 40–57. [in Russian]
20. Collins P, Webb CM1, de Villiers TJ еt al. Cardiovascular risk assessment in women – an update. Climacteric 2016; 19 (4): 329–36. DOI: 10.1080/13697137.2016.1198574. Epub 2016 Jun 21
21. Gass ML, Maki PM, Shifren JL et al. NAMS supports judicious use of systemic hormone therapy for women aged 65 years and older. Menopause 2015; 22 (7): 685–6. DOI: 10.1097/GME.0000000000000491
22. Schürmann R, Holler T, Benda N. Estradiol and drospirenone for climacteric symptoms in postmenopausal women: a double-blind, randomized, placebo-controlled study of the safety and efficacy of three dose regimens. Climacteric 2004; 7 (2): 189–96.
23. Gambacciani M, Rosano G, Cappagli B. Clinical and metabolic effects of drospirenone-estradiol in menopausal women: a prospective study. Climacteric 2011; 14 (1): 18–24. DOI: 10.3109/13697137.2010.520099. Epub 2010 Oct 27.
24. AGOS Practice BULLETTIN No 141: Management Of Menopausal Symptoms. Obstet Gynecol 2014; 123–202–216.
25. Instruktsiia po primeneniiu preparata Anzhelik Mikro. http://www.rlsnet.ru/tn_index_id_80329.htm [in Russian]
26. Archer DF, Schmelter Th, Schaefers M et al. A randomized, double-blind, placebo-controlled study of the lowest effective dose of drospirenone with 17b-estradiol for moderate to severe vasomotor symptoms in postmenopausal women. Menopause 2014; 21 ( 3): 227–35.DOI: 10.1097/GME.0b013e31829c1431
27. Genazzani AR, Schmelter T, Schaefers M. One-year randomized study of the endometrial safety and bleeding pattern of 0.25 mg drospirenone/0.5 mg 17b-estradiol in postmenopausal women. Climacteric 2013; 16: 490–8. DOI: 10.1056/NEJMoa1505241

Авторы

Т.В.Овсянникова*1, И.А.Куликов2

1. ФГАОУ ВО Российский университет дружбы народов. 117198, Россия, Москва, ул. Миклухо-Маклая, д. 6;
2. ГБОУ ВПО Первый Московский государственный медицинский университет им. И.М.Сеченова Минздрава России. 119991, Россия, Москва, ул. Трубецкая, д. 8, стр. 2
*dr.otoma@yandex.ru

________________________________________________

T.V.Ovsyannikova*1, I.A.Kulikov2

1. People’s Friendship University of Russia. 117198, Russian Federation, Moscow, ul. Miklukho-Maklaya, d. 6;
2. I.M.Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation. 119991, Russian Federation, Moscow, ul. Trubetskaya, d. 8, str. 2
*dr.otoma@yandex.ru

Назад к списку

Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.